415
Participants
Start Date
March 16, 2021
Primary Completion Date
July 19, 2022
Study Completion Date
December 21, 2022
Standard Induction Procedure (SP)
SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
Rapid Induction Procedure (RP)
RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
Stony Brook Eastern Long Island Hospital, Greenport
Avery Road Treatment Center, Rockville
Aspire Health Partners, Orlando
Gibson Recovery Center, Inc., Cape Girardeau
Nexus Recovery Center, Inc., Dallas
Adapt, Roseburg
National Institute on Drug Abuse (NIDA)
NIH
The Emmes Company, LLC
INDUSTRY
New York State Psychiatric Institute
OTHER